Promoting Effects of the Adipokine, Apelin, on Diabetic Nephropathy

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Zhang, Bao Hai ^a,b   Wang, Wenying ^c   Wang, Hongxia ^a   Yin, Jiming ^d   Zeng, Xiang Jun ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ANGIOPOIETIN RECEPTOR; APELIN; APELIN RECEPTOR; PEPTIDE ANTIBODY; VASCULOTROPIN RECEPTOR 2;

ALBUMIN BLOOD LEVEL; ALBUMINURIA; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CELL MIGRATION; CELL PERMEABILIZATION; CELL PROLIFERATION; CHEMOTAXIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC NEPHROPATHY; ENDOTHELIUM CELL; ENZYME REGULATION; GLOMERULUS; HUMAN; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN URINE LEVEL;

ADIPOKINES; ALBUMINURIA; ANIMALS; CELL MOVEMENT; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; ENDOTHELIAL CELLS; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY GLOMERULUS; MALE; MICE; MIDDLE AGED; PERMEABILITY; RECEPTOR, TIE-2; RECEPTORS, G-PROTEIN-COUPLED; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84875963180     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060457     Document Type: Article

References (41)

1. Vivian EM, (2006) Type 2 diabetes in children and adolescents-the next epidemic? Curr Med Res Opin 22: 297-306.
2. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, et al. (2003) RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 162: 1123-1137.
3. Guo M, Ricardo SD, Deane JA, Shi M, Cullen-McEwen L, et al. (2005) A stereological study of the renal glomerular vasculature in the db/db mouse model of diabetic nephropathy. J Anat 207: 813-821.
4. Nyengaard JR, Rasch R, (1993) The impact of experimental diabetes mellitus in rats on glomerular capillary number and sizes. Diabetologia 36: 189-194.
5. Haraldsson B, Sorensson J, (2004) Why do we not all have proteinuria? An update of our current understanding of the glomerular barrier. News Physiol Sci 19: 7-10.
6. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, et al. (1998) Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 251: 471-476.
7. Devic E, Rizzoti K, Bodin S, Knibiehler B, Audigier Y, (1999) Amino acid sequence and embryonic expression of msr/apj, the mouse homolog of Xenopus X-msr and human APJ. Mech Dev 84: 199-203.
8. Kleinz MJ, Davenport AP, (2004) Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Regul Pept 118: 119-125.
9. Soriguer F, Garrido-Sanchez L, Garcia-Serrano S, Garcia-Almeida JM, Garcia-Arnes J, et al. (2009) Apelin levels are increased in morbidly obese subjects with type 2 diabetes mellitus. Obes Surg 19: 1574-1580.
10. Cox CM, D'Agostino SL, Miller MK, Heimark RL, Krieg PA, (2006) Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. Dev Biol 296: 177-189.
11. Carmeliet P, (2000) Mechanisms of angiogenesis and arteriogenesis. Nat Med 6: 389-395.
12. Kasai A, Shintani N, Oda M, Kakuda M, Hashimoto H, et al. (2004) Apelin is a novel angiogenic factor in retinal endothelial cells. Biochem Biophys Res Commun 325: 395-400.
13. Kidoya H, Ueno M, Yamada Y, Mochizuki N, Nakata M, et al. (2008) Spatial and temporal role of the apelin/APJ system in the caliber size regulation of blood vessels during angiogenesis. EMBO J 27: 522-534.
14. Li F, Li L, Qin X, Pan W, Feng F, et al. (2008) Apelin-induced vascular smooth muscle cell proliferation: the regulation of cyclin D1. Front Biosci 13: 3786-3792.
15. Wang LY, Zhang DL, Zheng JF, Zhang Y, Zhang QD, et al. (2011) Apelin-13 passes through the ADMA-damaged endothelial barrier and acts on vascular smooth muscle cells. Peptides 32: 2436-2443.
16. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26 (Suppl 1): S5-20.
17. Tanimoto M, Fan Q, Gohda T, Shike T, Makita Y, et al. (2004) Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice. Metabolism 53: 1473-1479.
18. Zhu J, Su LP, Ye L, Lee KO, Ma JH, (2012) Thymosin beta 4 ameliorates hyperglycemia and improves insulin resistance of KK Cg-Ay/J mouse. Diabetes Res Clin Pract 96: 53-59.
19. Ott IM, Alter ML, von Websky K, Kretschmer A, Tsuprykov O, et al. (2012) Effects of Stimulation of Soluble Guanylate Cyclase on Diabetic Nephropathy in Diabetic eNOS Knockout Mice on Top of Angiotensin II Receptor Blockade. PLoS One 7: e42623.
20. Tasaki Y, Taguchi Y, Machida T, Kobayashi T, (2010) Relationship between growth retardation and impaired glucose tolerance in hypothyroidal growth-retarded (grt) mice. Congenit Anom (Kyoto) 50: 186-192.
21. Conti FG, Elliot SJ, Striker LJ, Striker GE, (1989) Binding of insulin-like growth factor-I by glomerular endothelial and epithelial cells: further evidence for IGF-I action in the renal glomerulus. Biochem Biophys Res Commun 163: 952-958.
22. Rosenson RS, Fioretto P, Dodson PM, (2011) Does microvascular disease predict macrovascular events in type 2 diabetes? Atherosclerosis 218: 13-18.
23. Brownlee M, (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820.
24. Endemann DH, Schiffrin EL, (2004) Endothelial dysfunction. J Am Soc Nephrol 15: 1983-1992.
25. Goligorsky MS, Chen J, Brodsky S, (2001) Workshop: endothelial cell dysfunction leading to diabetic nephropathy: focus on nitric oxide. Hypertension 37: 744-748.
26. Das Evcimen N, King GL, (2007) The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res 55: 498-510.
27. Hohenstein B, Hausknecht B, Boehmer K, Riess R, Brekken RA, et al. (2006) Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int 69: 1654-1661.
28. Kanesaki Y, Suzuki D, Uehara G, Toyoda M, Katoh T, et al. (2005) Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy. Am J Kidney Dis 45: 288-294.
29. Osterby R, Nyberg G, (1987) New vessel formation in the renal corpuscles in advanced diabetic glomerulopathy. J Diabet Complications 1: 122-127.
30. Osterby R, (1992) Glomerular structural changes in type 1 (insulin-dependent) diabetes mellitus: causes, consequences, and prevention. Diabetologia 35: 803-812.
31. Wehner H, Nelischer G, (1991) Morphometric investigations on intrarenal vessels of streptozotocin-diabetic rats. Virchows Arch A Pathol Anat Histopathol 419: 231-235.
32. Osterby R, Asplund J, Bangstad HJ, Nyberg G, Rudberg S, et al. (1999) Neovascularization at the vascular pole region in diabetic glomerulopathy. Nephrol Dial Transplant 14: 348-352.
33. Osterby R, Hartmann A, Bangstad HJ, (2002) Structural changes in renal arterioles in Type I diabetic patients. Diabetologia 45: 542-549.
34. Ichinose K, Maeshima Y, Yamamoto Y, Kinomura M, Hirokoshi K, et al. (2006) 2-(8-hydroxy-6-methoxy-1-oxo-1h-2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice. Diabetes 55: 1232-1242.
35. Nakagawa T, Sato W, Glushakova O, Heinig M, Clarke T, et al. (2007) Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol 18: 539-550.
36. Yamamoto Y, Maeshima Y, Kitayama H, Kitamura S, Takazawa Y, et al. (2004) Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes 53: 1831-1840.
37. Ziyadeh FN, Wolf G, (2008) Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev 4: 39-45.
38. Japp AG, Cruden NL, Amer DA, Li VK, Goudie EB, et al. (2008) Vascular effects of apelin in vivo in man. J Am Coll Cardiol 52: 908-913.
39. Petrova TV, Makinen T, Alitalo K, (1999) Signaling via vascular endothelial growth factor receptors. Exp Cell Res 253: 117-130.
40. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, et al. (2000) Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 6: 460-463.
41. Ward NL, Dumont DJ, (2002) The angiopoietins and Tie2/Tek: adding to the complexity of cardiovascular development. Semin Cell Dev Biol 13: 19-27.